Medical Properties Trust (MPT) As Refinancing And Earnings Progress Feed The Undervalued View
Why Medical Properties Trust is back in focus after second quarter results
Medical Properties Trust (MPT) is drawing fresh attention after its second quarter 2026 earnings, which showed a much smaller quarterly net loss and a return to net income for the first half.
The company reported second quarter sales of US$236.71 million and revenue of US$259.28 million, with a net loss of US$2.6 million and basic loss per share from continuing operations of US$0.01.
For the six months to June 30, 2026, sales were US$468.42 million and revenue was US$511.35 million. Net income was US$30.23 million, with basic earnings per share from continuing operations of US$0.05.
See our latest analysis for Medical Properties Trust.
Medical Properties Trust’s share price has fallen 20.3% year to date, including a 21.8% decline over the past three months and a 9.8% decline over the past month. At the same time, the 1 year total shareholder return of 5.3% points to modest recovery as investors weigh the smaller quarterly loss, ongoing refinancing plans and balance sheet risks.
If you are reassessing hospital real estate exposure, it can help to compare it with other income oriented ideas that still offer growth potential. One way to broaden that search is by checking out 19 top founder-led companies
Medical Properties Trust now looks like a large portfolio of hospital assets with a much smaller quarterly loss, but a share price that is still under pressure. Is this a solid business that the market is pricing too cautiously?
Most Popular Narrative: 30% Undervalued
On the most followed narrative, Medical Properties Trust’s fair value of $5.79 sits above the last close of $4.05, which puts the focus squarely on execution and balance sheet repair.
Elevated leverage and large-scale debt refinancings at higher interest rates (e.g., $2.5 billion in secured notes at nearly 8%) are increasing the company's cost of capital; unless rental growth outpaces interest costs, this dynamic will pressure AFFO, net earnings, and potentially dividend sustainability in the long run.
Want to see what kind of revenue profile and margin rebuild has to line up for that fair value to work? The narrative leans heavily on a shift from losses to sustained profitability, with a future earnings multiple that would usually be associated with faster growing sectors. Curious how those assumptions stack together to bridge the gap between $4.05 and $5.79.
Result: Fair Value of $5.79 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still real pressure points for Medical Properties Trust, including tenant concentration around re‑tenanted hospitals and higher refinancing costs on its sizeable debt stack.
Find out about the key risks to this Medical Properties Trust narrative.
Next Steps
Given the mixed tone around Medical Properties Trust, it makes sense to check the underlying numbers yourself and decide where you stand. To see both the potential upsides and the key areas of concern in one place, take a closer look at the 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Medical Properties Trust?
If you only stick with Medical Properties Trust, you might miss out on other stocks that better match your risk, income, or value goals.
- Target value opportunities by scanning 49 high quality undervalued stocks that combine solid fundamentals with room for a potential re rating.
- Build steadier income by reviewing 9 dividend fortresses that focus on higher yielding companies.
- Dial down risk by checking 85 resilient stocks with low risk scores that score well on resilience and financial strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com